BioCardia, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving BioCardia, Inc. now
Current reporting with the operating signal separated from the noise.
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
Investors are testing whether BioCardia, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.BioCardia, Inc. (BCDA) Q1 FY2026 earnings call transcript
Investors are testing whether BioCardia, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.BioCardia, Inc. Secures Japanese Patent for Innovative Catheter Delivery System in Cell Therapy
The story matters when it changes BioCardia, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: official volume, pricing, inventory and segment margin.BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript
Investors are testing whether BioCardia, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.BioCardia, Inc. Reports Third Quarter 2017 Financial Results and Business Highlights
The story matters when it changes BioCardia, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest BCDA filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
BioCardia, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →